In grade II and III gliomas and in all samples, the results showed that the survival rate of the GNG12 high expression group was lower than that of the low expression group, regardless of the presence of IDH mutations or 1p/19q co-deletions (Figures 3A, –C). This evidence concerns the gene IDH1 and central nervous system cancer.